AMLX Amylyx Pharmaceuticals, Inc.
Financings ·
Amylyx's final supplement prices 14,090,000 shares at $35.500 for $500,195,000 before costs, above the $350,000,000 in the first filing. The company announced Phase 3 topline results the same day.
We have not published a story on Amylyx Pharmaceuticals yet. When there is news, it will appear here.
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapies for endocrine conditions and neurodegenerative diseases. Its lead investigational asset, avexitide, is a first-in-class GLP-1 receptor antagonist. It has been evaluated for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism. The FDA has granted avexitide Breakthrough Therapy Designation for both PBH and hyperinsulinemic hypoglycemia, Rare Pediatric Disease Designation in congenital hyperinsulinism, and Orphan Drug Designation for hyperinsulinemic hypoglycemia. PBH is estimated to affect approximately 8% of people in the U.S. who have undergone sleeve gastrectomy or Roux-en-Y gastric bypass, and there are no approved therapies for it. The Phase 3 LUCIDITY trial is a randomized, double-blind, placebo-controlled study in participants with PBH after Roux-en-Y gastric bypass surgery. Recruitment is complete, with topline data expected in Q3 2026 and a commercial launch in 2027 if approved. The company says it matches investigational therapies to diseases based on mechanistic rationale, clinical outcomes and biomarkers, regardless of modality.
| Product or program | What it is | Stage |
|---|---|---|
| Avexitide | First-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism | Phase 3 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $90.4 million | $104.1 million |
| Net income (loss) | -$144.7 million | -$301.7 million |
| Cash from operations | -$123.3 million | -$167.6 million |
| Cash and equivalents | $226.7 million | $77.4 million |
| Short-term investments | $90.3 million | $99.1 million |
Our latest story on this, dated Aug 18, 2026: "Amylyx Pharmaceuticals launches $350,000,000 common stock offering". The story links the filing or release it is based on. Read the story.
Amylyx Pharmaceuticals, Inc. trades under the ticker AMLX on NASDAQ.
Amylyx Pharmaceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Amylyx Pharmaceuticals, Inc. is 1658551. Its filings are on SEC EDGAR.
111,423,048 shares as of 2026-07-27, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Amylyx Pharmaceuticals, Inc. under United States.
Our directory classifies Amylyx Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Amylyx Pharmaceuticals, Inc. is US03237H1014.
aibio.space lists Amylyx Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapies for endocrine conditions and neurodegenerative diseases. Its lead investigational asset, avexitide, is a first-in-class GLP-1 receptor antagonist.
Avexitide: First-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism Stage: Phase 3.
Amylyx Pharmaceuticals, Inc. reported a net loss of $144.7 million for the fiscal year ended Dec 31, 2025, and used $123.3 million of cash in operations, per its annual report to the SEC.
$90.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
$250.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio